We use cookies to improve the performance of our site and optimize it for our users. Customize Cookie Preferences

Sign Up Today and Learn More About Synergy Pharmaceuticals Stock

Invest in or calculate the value of your shares in Synergy Pharmaceuticals or other pre-IPO companies through EquityZen's platform.

Get Started

Synergy Pharmaceuticals Stock

Synergy Pharmaceuticals is a biopharmaceutical company developing novel therapies for the treatment of gastrointestinal conditions.

About Synergy Pharmaceuticals Stock

Founded

1992

Headquarters

New York, NY, US

Total Funding

407M

Industries

Software, Artificial Intelligence, Data and Analytics

Synergy Pharmaceuticals Inc., headquartered in New York, NY with laboratories in Doylestown, PA, is a biopharmaceutical company focused on the research and development of novel therapies for the treatment of chronic idiopathic constipation, irritable bowel syndrome with constipation and other difficult-to-treat gastrointestinal (GI) conditions. Synergy’s lead drug, plecanatide, and next-generation candidate, SP-333, are proprietary analogs of the natural human GI hormone, uroguanylin, and members of the new class of guanylate cyclase-C (“GC-C”) agonists.

Synergy Pharmaceuticals Press Mentions

Stay in the know about the latest news on Synergy Pharmaceuticals

Synergy Pharmaceuticals Moves Forward on Path Toward Sale

Wall Streets Journal • Dec 14, 2018

Synergy Pharmaceuticals Management

Leadership team at Synergy Pharmaceuticals

President & CEO

Gary S. Jacob

CMO

Patrick H. Griffin

Locked Features

Join now and verify your accreditation status to gain access to:

  • Synergy Pharmaceuticals current valuation
  • Synergy Pharmaceuticals stock price
  • Available deals in Synergy Pharmaceuticals and all other companies
  • Deal offering documents
  • EquityZen's proprietary data and insights, including
    • Cap tables, which include funding history by Share Class and Liquidity Preferences
    • Company Highlights
    • Business Model
    • Risk Factors
Join Now

Trading Synergy Pharmaceuticals Stock

How to invest in Synergy Pharmaceuticals stock?

Accredited investors can buy pre-IPO stock in companies like Synergy Pharmaceuticals through EquityZen funds. These investments are made available by existing Synergy Pharmaceuticals shareholders who sell their shares on our platform. Typically, these are early employees who need to fund a life event – house, education, etc. Accredited investors are then offered the opportunity to invest in this stock through a fund, like those used by hedge funds serving large investors. While not without risk, investing in private companies can help investors reach goals of portfolio diversification, access to potential growth and high potential return. Learn more about our Guided Investment process here.

How to sell Synergy Pharmaceuticals stock?

Shareholders can sell their Synergy Pharmaceuticals stock through EquityZen's private company marketplace. EquityZen's network includes over 330K accredited investors interested in buying private company stock. Learn more about the easy and guided Shareholder process here.

If I invest, how do I exit my investment?

There are two ways to exit your private company investment on EquityZen's marketplace. The first is if the company has an exit event like an IPO, merger or acquisition. In that case, we will distribute the shares and/or cash to you directly. The second way is through an Express Deal on EquityZen, if eligible. An Express Deal allows you to sell your allocation of private shares in a given private company to another investor on EquityZen's marketplace. More information on Express Deals can be found here and exit information can be found here.

Why choose EquityZen?

Since 2013, the EquityZen marketplace has made it easy to buy and sell shares in private companies. EquityZen brings together investors and shareholders, providing liquidity to early shareholders and private market access to accredited investors. With low investment minimums through our funds and with more than 43K private placements completed across 450+ companies, EquityZen leads the way in delivering "Private Markets for the Public."